Acumen Pharmaceuticals, Inc. Stock Price, News & Analysis

Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report its fourth quarter and year-end 2022 financial results on March 27, 2023. The company is focused on developing ACU193, a novel therapeutic targeting soluble amyloid beta oligomers for Alzheimer’s disease treatment. A conference call and live audio webcast will occur at 8:00 a.m. ET for a business and financial update. This important milestone is part of Acumen's efforts in advancing its investigational product candidate, which is currently in a Phase 1 clinical trial.

Acumen Pharmaceuticals (NASDAQ: ABOS), a biopharmaceutical company targeting Alzheimer's disease, will participate in the Needham Virtual Neuroscience Forum on March 15, 2023, at 10:00 a.m. ET. The company focuses on developing ACU193, a humanized monoclonal antibody aimed at combating toxic soluble amyloid beta oligomers, a key contributor to Alzheimer’s pathology. The live webcast can be accessed under the Investors tab on their website and will be available for 14 days post-event. Founded by researchers in amyloid beta oligomers, Acumen is advancing its Phase 1 clinical trial, INTERCEPT-AD, for early Alzheimer’s patients.

Acumen Pharmaceuticals (NASDAQ: ABOS) has completed enrollment for its Phase 1 INTERCEPT-AD trial of ACU193, a monoclonal antibody targeting toxic soluble amyloid beta oligomers, aimed at treating Alzheimer’s disease. A total of 65 subjects were enrolled across 17 sites in the U.S. Results, including safety and proof-of-mechanism data, are expected by Q3 2023, earlier than anticipated. ACU193 is the first antibody developed to selectively target these oligomers, which are linked to neurodegeneration in Alzheimer’s.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced the appointment of Dr. Derrell Porter to its Board of Directors on January 4, 2023. Dr. Porter, a physician-entrepreneur with over 20 years of experience in drug development, will enhance Acumen’s strategic direction as it advances clinical trials for ACU193, a potential disease-modifying treatment for Alzheimer’s disease. This humanized monoclonal antibody targets toxic soluble AβOs, aiming to mitigate neurodegeneration associated with Alzheimer's. ACU193 has received Fast Track designation from the FDA.

Acumen Pharmaceuticals (NASDAQ: ABOS) announced progress in its Phase 1 INTERCEPT-AD trial for ACU193, targeting early Alzheimer’s disease, with enrollment expected to complete by Q1 2023. The FDA granted Fast Track designation to ACU193, facilitating closer collaboration during development. As of September 30, 2022, Acumen reported cash and equivalents of $200.2 million, expected to fund operations through 2025. Q3 2022 net loss was $10.7 million, up from $3.9 million in Q3 2021, primarily due to increased R&D and G&A expenses. A conference call detailing these updates took place on November 14, 2022.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in a fireside chat at the Stifel Healthcare Conference on November 16, 2022, at 4:10 p.m. ET. The live webcast will be accessible under the Investors tab on Acumen's website, where it will be archived for 14 days.

Acumen focuses on developing novel therapeutics for Alzheimer’s disease, targeting toxic soluble AβOs with its investigational product candidate, ACU193, currently in a Phase 1 clinical trial for early Alzheimer’s patients.

Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q3 2022 financial results on November 14, 2022, followed by a conference call at 4:30 p.m. ET. This call aims to provide a comprehensive business and financial update regarding the company's operations. Acumen is focused on developing innovative therapeutics for Alzheimer's disease, specifically targeting soluble AβOs with its candidate ACU193 in a Phase 1 clinical trial.

Acumen Pharmaceuticals announced the publication of its clinical development plan for ACU193, a monoclonal antibody targeting toxic soluble amyloid beta oligomers, in the Journal of Prevention of Alzheimer’s Disease. The ongoing Phase 1 clinical trial, INTERCEPT-AD, aims to evaluate the safety and efficacy of ACU193 in early Alzheimer’s disease patients. The FDA has granted Fast Track designation for this therapy, which may accelerate its path to market. Future trial phases will be guided by safety, pharmacokinetics, and cognitive measures for potential registration.

Acumen Pharmaceuticals (NASDAQ: ABOS) announced that its investigational drug, ACU193, has received Fast Track designation from the FDA for treating early Alzheimer’s disease. ACU193 targets toxic soluble amyloid beta oligomers, which are believed to contribute to neurodegeneration. Currently in the Phase 1 INTERCEPT-AD trial, the drug aims to establish safety and proof of mechanism with 62 participants. The Fast Track status facilitates closer collaboration with the FDA, enhancing the potential for expedited review and approval.